Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05116826 · ClinicalTrials.gov registry record · Phase 1
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
A Phase 1 study of Liver Diseases and Moderate Hepatic Impairment, sponsored by Genfit.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT05116826: Completed Phase 1 study of Liver Diseases and Moderate Hepatic Impairment, sponsored by Genfit.
NCT05116826 is a Phase 1 study of Liver Diseases and Moderate Hepatic Impairment that has completed, run by Genfit. The registered enrollment target is 25 participants, below the 61,158-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05116826, a Phase 1 study of Liver Diseases and Moderate Hepatic Impairment, has completed, sponsored by Genfit.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with hepatic impairment and healthy adults.
Primary Outcome
In participants with moderate and severe hepatic impairment compared to healthy volunteers
Conditions Studied
Interventions
- DRUG Nitazoxanide
Study Locations (2)
Florida
- Panax Clinical Research - Miami Lakes
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-11-05 |
| Est. Completion | 2022-04-13 |
| Phase | Phase 1 |
What the finished NCT05116826 record still lists
NCT05116826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 61,158-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Liver Diseases appearing as the primary indexed condition, and to 1 intervention - of which Nitazoxanide is the first listed.
NCT05116826 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05116826 about?
NCT05116826 is a clinical study titled "Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients". This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with hepatic impairment and healthy adults.
What is the current status of trial NCT05116826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-11-05. Estimated completion is 2022-04-13.
What conditions does trial NCT05116826 study?
This clinical trial studies the following conditions: Liver Diseases, Moderate Hepatic Impairment, Severe Hepatic Impairment.
What interventions are being tested in trial NCT05116826?
The interventions under investigation include: Nitazoxanide (DRUG).
Who is sponsoring clinical trial NCT05116826?
This trial is sponsored by Genfit, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05116826 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05116826's enrollment target sits among peer trials
25 30th of 33 higher than 3 of 33 other Liver Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
RECRUITING · Phase 1
-
A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems
COMPLETED · Phase 1
-
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
COMPLETED · Phase 1
-
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
RECRUITING · NA
-
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
RECRUITING · NA
-
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI